Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity - Pfizer
- Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity Pfizer
- Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects CNBC
- Pfizer Stops Developing Weight-Loss Pill Bloomberg Television
- Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal STAT
- Pfizer Stock Heads for Lowest Level Since 2020 After Obesity-Drug Setback The Wall Street Journal
- View Full Coverage on Google News